Oncternal Therapeutics to Participate in the Cantor

0
51


SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical firm targeted on the growth of novel oncology therapies, right this moment introduced that administration will take part in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.

James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer, will take part in particular person in the “Multiple Myeloma & Lymphoma” panel at 4:15pm (ET) at the Hubbard Room I, and the Company will host one-on-one conferences.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical firm targeted on the growth of novel oncology therapies for the therapy of sufferers with cancers which have important unmet medical want. Oncternal pursues drug growth concentrating on promising, but untapped organic pathways implicated in most cancers era or development, specializing in hematological malignancies and prostate most cancers. The lead medical program is zilovertamab, an investigational monoclonal antibody designed to inhibit the perform of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). Zilovertamab is being evaluated in an ongoing Phase 1/2 examine in mixture with ibrutinib for the therapy of sufferers with mantle cell lymphoma (MCL) and power lymphocytic leukemia (CLL), and was lately amended to embrace sufferers with marginal zone lymphoma (MZL). Zilovertamab can be being evaluated in two investigator-initiated research, together with a Phase 2 medical trial of zilovertamab in mixture with venetoclax, a Bcl-2 inhibitor, in sufferers with relapsed/refractory CLL, and in a Phase 1b examine of zilovertamab in mixture with docetaxel in sufferers with metastatic castration-resistant prostate most cancers (mCRPC). Oncternal can be creating ONCT-808, an autologous chimeric antigen receptor T (CAR T) cell remedy that targets ROR1. Oncternal submitted its first IND for ONCT-808 in August 2022, for the therapy of sufferers with relapsed or refractory aggressive B cell lymphoma, together with sufferers who’ve failed earlier CD19 CAR T therapy. The early-stage pipeline additionally consists of ONCT-534, a dual-action androgen receptor inhibitor (DAARI) that’s present process closing IND-enabling research, as a possible therapy for castration resistant prostate most cancers, together with these with unmet medical want due to resistance to accredited, customary of care androgen receptor inhibitors. More info is out there at https://oncternal.com/.

See also  India's COVID-19 caseload nears 60 lakh; recoveries cross 49 lakh

Contact Information:

Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com

Media
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
cdavis@lifesciadvisors.com



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here